CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
New England Journal of Medicine · 02.04.2026 · 394 (13) · 1281-1291
DOI: 10.1056/nejmoa2415550 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.04.2026. Verfasst von Rabi Hanna und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Fetal Hemoglobin, gamma-Globins. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Editas Medicine, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland.
- Sarah Cannon Research Institute, Nashville.
- TriStar Centennial Children's Hospital, Nashville.
- Blood and Marrow Transplant Program and Marrow Processing Laboratory, Baylor University Medical Center, Dallas.
- Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.
- Bone Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York.
ORCID-Profile: Rabi Hanna, Haydar Frangoul, Akshay Sharma, Keunpyo Kim, Mark C Walters
Förderung
- Editas Medicine, Inc.
Zitieren
APA
Hanna, R., Frangoul, H., Pineiro, L., McKinney, C., Mapara, M., Dalal, J., Rangarajan, H. G., Atkins, H., Sharma, A., Chang, K. H., Jaskolka, M. C., Kim, K., Yu, Q., Mei, B., Afonja, O., Walters, M. C., & RUBY Investigators (2026). CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine, 394(13), 1281-1291. https://doi.org/10.1056/nejmoa2415550
Vancouver
Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, et al. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine. 2026;394(13):1281-1291. doi:10.1056/nejmoa2415550
BibTeX
@article{Hanna2026,
author = {Hanna, Rabi and Frangoul, Haydar and Pineiro, Luis and McKinney, Christopher and Mapara, Markus and Dalal, Jignesh and Rangarajan, Hemalatha G and Atkins, Harold and Sharma, Akshay and Chang, Kai-Hsin and Jaskolka, Michael C and Kim, Keunpyo and Yu, Qifeng and Mei, Baisong and Afonja, Olubunmi and Walters, Mark C and RUBY Investigators, RUBY Investigators},
title = {CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {13},
pages = {1281--1291},
doi = {10.1056/nejmoa2415550}
}
EUVIMED